相关实验视频
Updated: Jul 21, 2026
07:58
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
13.8K
通过循环瘤DNA分析识别的基因组放大指导转移性割抵抗性前列腺癌的预后
Toros A Dincman1,2,3, Joseph A Q Karam3, Antonio Giordano1,2,4,5
1Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC, United States.
Frontiers in oncology
|March 7, 2024
概括
在转移性前列腺癌 (mPC) 中循环瘤DNA (ctDNA) 分析揭示了与疾病进展相关的基因放大 (GA). 特定的GA影响整体存活率 (OS),较少的GA与mPC患者的改善OS相关.
科学领域:
- 基因组医学是基因组医学.
- 在瘤学瘤学.
- 分子诊断学 分子诊断学
背景情况:
- 循环瘤DNA (ctDNA) 分析为转移性前列腺癌 (mPC) 的基因组改变提供了洞察力.
- 监测ctDNA可以在治疗期间识别基因放大 (GA) 和血拷贝数 (PCN) 改变.
研究的目的:
- 评估特定基因放大 (GA) 和血拷贝数 (PCN) 变化与mPC患者疾病特征之间的关联.
- 为了确定GAs在转移性割抵抗性前列腺癌 (mCRPC) 的预后价值.
主要方法:
- 通过Guardant360.0进行CTDNA分析的155名mPC患者的回顾性分析.
- 用于生存分析的卡普兰-梅尔和考克斯回归模型 (OS,FFS).
- 奇方位测试用于评估临床因素和GA之间的关联.
主要成果:
- 与BRAF,CDK6,PI3KCA和FGFR1GA相关的肝/肺转移.
- 在mCRPC患者中,较少的GA与改善的整体存活 (OS) 相关联.
- PIK3CA GA与显著降低的OS相关;AR/MYC 在治疗期间PCN减少与改善的OS相关.
结论:
- 在ctDNA中的特定GA与mPC中的生存结果有关.
- ctDNA GA分析有助于mCRPC预后和治疗指南.
- 对ctDNA GAs的连续监测可以告知治疗反应和预后.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...